Cancer revolution

Cancer continues to impact millions of people around the world. In 2018 there were over 17 million new cancer cases and by 2040, the numbers are expected to grow to 27.5 million. With this growing global burden, it is critical for organisations to push the boundaries of science to make curing cancer a reality.

AstraZeneca is leading a revolution in oncology to redefine cancer care. Their ambition is to provide cures for cancer in all its forms. The organisation is conducting cancer research to better understand all the complexities of the disease in order to discover, develop and deliver life-changing treatments.

This means putting patients first when it comes to developing new medicines. They consider the complete experience, from the way that medicines affect the body to making treatment regimens as convenient as possible.

Its employees strive every day to make cure a reality for the millions of people across the world living with cancer. They focus on some of the most hostile and hard-to-treat cancers, including lung, breast, ovarian, gastro-intestinal, genitourinary and blood cancers.

Priority is placed on areas of research that have the greatest opportunity to transform survival. They take pride in pushing the boundaries of science and challenging conventional thinking to identify new possibilities and ways to target the disease and drivers of it. Its teams have been working hard to identify new biomarkers (personal factors such as an individual’s DNA), crucial to identifying which approaches will have the best chance of success for each individual and their form of cancer.

Detecting cancer earlier can give diagnosed people more treatment options and increase their likelihood of survival. Early detection is the goal, but unfortunately not always the reality. For many people cancer goes undetected until it is in advanced stages.

For this reason, it is important to address the whole spectrum of cancer. The organisation develops medicines for use from the early stages to more advanced cancer. This commitment to providing a full spectrum of treatment regimens means the organisation has one of the most diverse portfolios of cancer medicines in the industry today.

Most cancers have vulnerabilities based on the way they depend on the body for growth. Although discovering these drivers of disease can be challenging. AstraZeneca is employing new approaches in drug discovery and delivery, including artificial intelligence (AI) and data science, to get the upper hand in the fight against cancer. Leveraging technology has enabled them to improve the speed of clinical trials, make better use of data, and embrace AI and machine learning to revolutionise clinical trial design.

Despite huge advances in cancer care over recent decades, many challenges remain before cure can truly be achieved. AstraZeneca believes that defeating cancer requires a collective and collaborative approach with the cancer community. From drug discovery collaborations to commercial partnerships, they leave no stone unturned to maximise the opportunities through shared knowledge and experience. This is testament to their ambition to revolutionise cancer care.